Business Wire

SOLAR-PROMOTION-GMBH

7.5.2024 17:54:32 CEST | Business Wire | Press release

Share
Fields and the Sun: Agricultural PV, an Opportunity for the Energy and the Farming Industry

The EU’s objectives are ambitious: The total solar energy deployment is to reach around 750 gigawatts by 2030. In this context, dual land use concepts, especially agricultural PV, are gaining importance. At Intersolar Europe, the world’s leading exhibition for the solar industry, visitors will have the opportunity to see a varied range of technologies, products and solutions for agricultural PV, and to gain deeper insights into best practices and the latest developments. Intersolar Europe will take place from June 19–21, 2024 as part of The smarter E Europe, the continent’s largest alliance of exhibitions for the energy industry, in Munich.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240507054567/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Latest tracking systems for agricultural PV applications will be presented at the "Intersolar Europe Special Exhibit Agrivoltaics". (© BayWa r.e.)

Agriculture or renewable sources of energy – in the past, it was either, or. Agricultural PV is a new, innovative approach offering promising options for agriculture and climate protection by joining agricultural production and the generation of electricity on the same surface.

Extensive subsidies

European countries such as Germany and France subsidize agricultural PV with the aim of deploying more solar energy while reducing the competition for land use. Germany has introduced a separate auction segment with a top value for “special solar installation” (which includes agricultural PV installations) in the Solar Package 1, and France is deemed one of the pioneers for dedicated legislation. Other countries, such as Austria and the Netherlands, also promote their agricultural PV sector.

Benefits of agricultural PV

The advantages of dual land use are obvious: It reconciles solar energy with agriculture, and the protection against storm, hale, frost and draught adds an extra bonus for farmers. The electricity production costs are lower than from small roof-mounted installations, and farmers’ income is diversified. Shading and wind protection provided by solar panels reduces evaporation, and innovative solar panels have been developed that also collect rainwater for irrigation. This can benefit farming operations by boosting their resilience against crop failure.

Best practice projects

Pilot projects are emerging all over Europe. In the Dutch local authority of Meierijstad, for example, BayWa r.e. AG and their subsidiary GroenLeven are implementing a pioneering agricultural PV project, a 8.7 megawatt peak solar installation covering a vast raspberry plantation. On Sicily, figs and olives grow between the module rows of Europe’s largest agricultural PV plant. In Neißeaue, Germany, Next2Sun Technology works on a 20 megawatts solar farm with vertical modules.

Intersolar Europe 2024: special attention on agricultural PV

Intersolar Europe is putting a particular focus on agricultural PV. A special exhibit in the Outdoor Area will be dedicated to the topic. Partners of the special exhibit are BayWa AG, BayWa r.e., Conexio PSE, Vista Geo and ZIMMERMANN PV-Steel Group. What’s more, of the more than 1,370 Intersolar Europe exhibitors, some 60 exhibitors will be showcasing agricultural PV products and solutions. Experts will dive deeper into the topic and offer even wider information at a number of sessions at the Intersolar Forum and the Intersolar Europe Conference.

Intersolar Europe

As the world’s leading exhibition for the solar industry, Intersolar Europe demonstrates the enormous vitality of the solar market. For more than 30 years, it has been providing a networking opportunity for key players, focusing on the latest trends, developments and business models under the motto “Connecting Solar Business”. Intersolar Europe will take place from June 19–21, 2024 as part of The smarter E Europe at Messe München.

Further information: www.intersolar.de/en.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240507054567/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye